Interpace Diagnostics® Continues to Offer PancraGEN® and Fluid Chemistry Testing
The Genetic Testing for Oncology LCD (L39365), posted for notice on June 2, 2023 by Novitas Solutions, Inc., will not become effective on July 17, 2023.
As a result, Interpace Diagnostics® is able to continue offering PancraGEN® and the related Point2® fluid chemistry tests for amylase, CEA, and glucose.
We thank our valued customers for your strong support of our testing services. We encourage you to continue sharing your perspectives on the importance and value of PancraGEN with Novitas Solutions, Inc.
PancraGEN and Point2 Fluid Chemistry Tests for Amylase, CEA and Glucose Continue to be Available
Questions regarding this update or relating to PancraGEN and the Point2 fluid chemistry tests can be addressed by contacting Interpace Client Services.
(800) 495-9655 or email@example.com